{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:10:35Z","timestamp":1792185035015,"version":"4.4.0"},"reference-count":109,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:sec id=\"ab-jrv250039-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Opioid use disorder (OUD) involves compulsive opioid use that causes substantial distress or impairment at work, school, or home. OUD, which is the third most prevalent substance use disorder worldwide, affected an estimated 3.7% of US adults (9\u202f367\u202f000) in 2022 and caused 53\u202f774 deaths in the US in 2024. Medications for opioid use disorder (MOUD) reduce morbidity and mortality. Individuals with OUD also benefit from medications to treat opioid withdrawal and reverse acute opioid overdose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250039-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Methadone, buprenorphine, and naltrexone are medications approved by the US Food and Drug Administration (FDA) to reduce unregulated opioid use. Methadone and buprenorphine reduce the risks of overdose and all-cause mortality. However, only 25.1% of people in the US with OUD were treated with these medications in 2022. MOUD should be selected based on shared decision-making that considers availability and convenience of treatment options and patient preferences. Buprenorphine and naltrexone are prescribed in office-based settings and can be taken at home. Outpatients with OUD in the US can only obtain methadone in person at federally regulated clinics. After stopping or substantially reducing use of opioids, individuals with OUD develop symptoms of opioid withdrawal, such as anxiety, insomnia, pain, nausea, vomiting, and diarrhea. Medications for opioid withdrawal include opioid agonists (eg, methadone and buprenorphine), \u03b1\n                      <jats:sub>2<\/jats:sub>\n                      -receptor agonists (eg, lofexidine and clonidine), and medications to treat pain (ibuprofen) and nausea (ondansetron). Individuals being treated for acute withdrawal should also be prescribed MOUD to decrease the risk of all-cause mortality (adjusted hazard ratio, 0.52; 95% CI, 0.42-0.63 for MOUD vs no MOUD). Individuals who use opioids may develop opioid overdose, which can cause respiratory depression, stupor, and, if severe, coma and death. Opioid overdose can be treated or can be reversed with naloxone, an opioid antagonist that is FDA approved and should be administered at the lowest dose needed to restore a normal respiratory rate (eg, naloxone 0.4 mg intramuscularly or 2-4 mg intranasally). Community-wide distribution of naloxone to people who use opioids and their social networks has been associated with 25% to 46% lower community opioid overdose rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250039-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>\n                      All individuals with OUD should be offered treatment with MOUD to reduce opioid use. Methadone and buprenorphine decrease opioid-associated and all-cause mortality in patients with OUD. Opioid withdrawal symptoms may be treated with opioid agonists, \u03b1\n                      <jats:sub>2<\/jats:sub>\n                      -receptor agonists, and medications for pain and nausea. All individuals with OUD should have access to opioid antagonists, such as naloxone, to treat opioid overdose.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.26348","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:30:25Z","timestamp":1770827425000},"page":"986","source":"Crossref","is-referenced-by-count":29,"title":["Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose"],"prefix":"10.1001","volume":"335","author":[{"given":"Miriam T. H.","family":"Harris","sequence":"first","affiliation":[{"name":"Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe M.","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[{"name":"Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10208","key":"jrv250039r2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action.","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"jrv250039r3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates\u2014United States, 2022.","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"jrv250039r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100813","article-title":"Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: a mortality data analysis from 2019 to 2022.","volume":"36","author":"H\u00e9bert","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"jrv250039r6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/add.14144","article-title":"Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999-2015.","volume":"113","author":"Ruhm","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"jrv250039r8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2105\/AJPH.2023.307550","article-title":"An overlooked emergency: more than one in eight US adults have had their lives disrupted by drug overdose deaths.","volume":"114","author":"Athey","year":"2024","journal-title":"Am J Public Health"},{"issue":"1","key":"jrv250039r9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: implications for treatment.","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci Pract Perspect"},{"issue":"8","key":"jrv250039r10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis.","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"jrv250039r11","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/add.15818","article-title":"Clinical management of opioid withdrawal.","volume":"117","author":"Torres-Lockhart","year":"2022","journal-title":"Addiction"},{"issue":"2","key":"jrv250039r12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS).","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"jrv250039r14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","article-title":"The pharmacology of buprenorphine microinduction for opioid use disorder.","volume":"41","author":"De Aquino","year":"2021","journal-title":"Clin Drug Investig"},{"key":"jrv250039r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108646","article-title":"Treatment options and shared decision-making in the treatment of opioid use disorder: a scoping review.","volume":"135","author":"Marshall","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"jrv250039r16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"jrv250039r17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"jrv250039r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103872","article-title":"Interventions to prevent HIV and hepatitis C among people who inject drugs: latest evidence of effectiveness from a systematic review (2011 to 2020).","volume":"109","author":"Palmateer","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"2","key":"jrv250039r19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001333.pub3","article-title":"Oral naltrexone maintenance treatment for opioid dependence.","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"10118","key":"jrv250039r20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"jrv250039r21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006140.pub3","article-title":"Sustained-release naltrexone for opioid dependence.","volume":"5","author":"Korn\u00f8r","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"jrv250039r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112789","article-title":"Extended-release naltrexone versus oral naltrexone for substance use disorders: a systematic review and meta-analysis.","volume":"274","author":"Elmosalamy","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"jrv250039r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109497","article-title":"Bridge clinic implementation of \u201c72-hour rule\u201d methadone for opioid withdrawal management: impact on opioid treatment program linkage and retention in care.","volume":"236","author":"Taylor","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"jrv250039r24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"6","key":"jrv250039r25","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/add.70002","article-title":"The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021.","volume":"120","author":"Stringfellow","year":"2025","journal-title":"Addiction"},{"issue":"9","key":"jrv250039r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl.","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"jrv250039r30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach.","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"issue":"7","key":"jrv250039r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder.","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"14","key":"jrv250039r32","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jama.2024.27976","article-title":"Emergency clinician buprenorphine initiation, subsequent prescriptions, and continuous prescriptions.","volume":"333","author":"Dekker","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"jrv250039r33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamainternmed.2023.7282","article-title":"Caring for hospitalized adults with opioid use disorder in the era of fentanyl: a review.","volume":"184","author":"Englander","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"8","key":"jrv250039r34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.27016","article-title":"Injectable-only overlapping buprenorphine starting protocol in a low-threshold setting.","volume":"8","author":"Waters","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"jrv250039r35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/ADM.0000000000001356","article-title":"The impact of high-potency synthetic opioids on pharmacotherapies for opioid use disorder: a scoping review.","volume":"18","author":"Jegede","year":"2024","journal-title":"J Addict Med"},{"issue":"2","key":"jrv250039r36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/ADM.0000000000001267","article-title":"Associations of methadone and BUP\/NX dose titration patterns with retention in treatment and opioid use in individuals with prescription-type opioid use disorder: secondary analysis of the OPTIMA study.","volume":"18","author":"Bakouni","year":"2024","journal-title":"J Addict Med"},{"issue":"4","key":"jrv250039r37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001296","article-title":"High-dose buprenorphine initiation: a scoping review.","volume":"18","author":"Wong","year":"2024","journal-title":"J Addict Med"},{"key":"jrv250039r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108316","article-title":"Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series.","volume":"126","author":"Peckham","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"jrv250039r39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ajad.13484","article-title":"Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.","volume":"33","author":"Mariani","year":"2024","journal-title":"Am J Addict"},{"issue":"4","key":"jrv250039r40","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1097\/ADM.0000000000001136","article-title":"Inpatient low-dose transitions from full agonist opioids including methadone onto long-acting depot buprenorphine: case series from a multicenter clinical trial.","volume":"17","author":"Seval","year":"2023","journal-title":"J Addict Med"},{"key":"jrv250039r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109445","article-title":"Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder.","volume":"235","author":"Golan","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"jrv250039r42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.drugpo.2010.01.010","article-title":"Quality of life among opiate-dependent individuals: a review of the literature.","volume":"21","author":"De Maeyer","year":"2010","journal-title":"Int J Drug Policy"},{"issue":"2","key":"jrv250039r44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"jrv250039r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109254","article-title":"Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.","volume":"231","author":"Evans","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"jrv250039r46","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/add.70000","article-title":"Relative risks of adverse effects across different opioid agonist treatments\u2014a systematic review and meta-analysis.","volume":"120","author":"Meyer","year":"2025","journal-title":"Addiction"},{"key":"jrv250039r47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugalcdep.2017.09.024","article-title":"Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment.","volume":"181","author":"Haber","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"jrv250039r48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S2213-8587(19)30254-2","article-title":"Opioid-induced endocrinopathies.","volume":"8","author":"Fountas","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"jrv250039r49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jsxm.2017.12.004","article-title":"Plasma testosterone and sexual function in Southeast Asian men receiving methadone and buprenorphine maintenance treatment.","volume":"15","author":"Yee","year":"2018","journal-title":"J Sex Med"},{"issue":"2","key":"jrv250039r50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2605.2007.00824.x","article-title":"Hypogonadism in men receiving methadone and buprenorphine maintenance treatment.","volume":"32","author":"Hallinan","year":"2009","journal-title":"Int J Androl"},{"issue":"5","key":"jrv250039r51","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial.","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"14","key":"jrv250039r52","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"jrv250039r53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","article-title":"Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society.","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"issue":"5","key":"jrv250039r55","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/ADM.0000000000001362","article-title":"Induction to methadone 80 mg in the first week of treatment of patients who use fentanyl: a case series from an outpatient opioid treatment program.","volume":"18","author":"Steiger","year":"2024","journal-title":"J Addict Med"},{"key":"jrv250039r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108832","article-title":"Adapting methadone inductions to the fentanyl era.","volume":"141","author":"Buresh","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"jrv250039r57","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/ADM.0000000000001207","article-title":"Safety and efficacy of rapid methadone titration for opioid use disorder in an inpatient setting: a retrospective cohort study.","volume":"17","author":"Klaire","year":"2023","journal-title":"J Addict Med"},{"issue":"2","key":"jrv250039r59","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review.","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"jrv250039r60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","article-title":"Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder.","volume":"14","author":"Crotty","year":"2020","journal-title":"J Addict Med"},{"issue":"S2","key":"jrv250039r62","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists.","volume":"112","author":"Simon","year":"2022","journal-title":"Am J Public Health"},{"issue":"1","key":"jrv250039r63","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxad018","article-title":"Recent modifications to the US methadone treatment system are a Band-Aid-not a solution-to the nation\u2019s broken opioid use disorder treatment system.","volume":"1","author":"Krawczyk","year":"2023","journal-title":"Health Aff Sch"},{"issue":"3","key":"jrv250039r64","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/ADM.0000000000001281","article-title":"Novel uses of methadone under the \u201c72-hour rule\u201d to facilitate transitions of care and low-dose buprenorphine induction in an outpatient bridge clinic.","volume":"18","author":"Shahlapour","year":"2024","journal-title":"J Addict Med"},{"issue":"3","key":"jrv250039r66","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy.","volume":"8","author":"Krawczyk","year":"2023","journal-title":"Lancet Public Health"},{"issue":"10","key":"jrv250039r67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274094","article-title":"Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.","volume":"17","author":"Meyerson","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"jrv250039r68","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","article-title":"The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.","volume":"93","author":"Marsch","year":"1998","journal-title":"Addiction"},{"key":"jrv250039r69","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107823","article-title":"The effect of methadone on the hypothalamic pituitary gonadal axis and sexual function: a systematic review.","volume":"207","author":"Ortman","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"jrv250039r70","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1360-0443.2005.01091.x","article-title":"Menstrual cycle length during methadone maintenance.","volume":"100","author":"Schmittner","year":"2005","journal-title":"Addiction"},{"issue":"6","key":"jrv250039r71","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1360-0443.2009.02549.x","article-title":"Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.","volume":"104","author":"Anchersen","year":"2009","journal-title":"Addiction"},{"issue":"6","key":"jrv250039r72","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ADM.0000000000000353","article-title":"Methadone and the QTc interval: paucity of clinically significant factors in a retrospective cohort.","volume":"11","author":"Bart","year":"2017","journal-title":"J Addict Med"},{"issue":"4","key":"jrv250039r73","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline.","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"issue":"6","key":"jrv250039r74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008939.pub2","article-title":"QTc interval screening for cardiac risk in methadone treatment of opioid dependence.","volume":"2013","author":"Pani","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"jrv250039r75","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder.","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"jrv250039r76","first-page":"1207","article-title":"Duration of occupancy of opiate receptors by naltrexone.","volume":"29","author":"Lee","year":"1988","journal-title":"J Nucl Med"},{"issue":"4","key":"jrv250039r77","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders.","volume":"375","author":"Schuckit","year":"2016","journal-title":"N Engl J Med"},{"issue":"1-3","key":"jrv250039r78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.","volume":"123","author":"Bigelow","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"jrv250039r79","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial.","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"jrv250039r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104487","article-title":"Comparing methadone policy and practice in France and the US: implications for US policy reform.","volume":"129","author":"Englander","year":"2024","journal-title":"Int J Drug Policy"},{"key":"jrv250039r81","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies.","volume":"74","author":"Priest","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"4","key":"jrv250039r82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/YCO.0000000000000943","article-title":"Pharmacist-prescriber collaborative models of care for opioid use disorder: an overview of recent research.","volume":"37","author":"Cheetham","year":"2024","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"jrv250039r83","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025799","article-title":"Slow release oral morphine versus methadone for the treatment of opioid use disorder.","volume":"9","author":"Klimas","year":"2019","journal-title":"BMJ Open"},{"key":"jrv250039r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.105993","article-title":"Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): protocol for a non-inferiority randomized clinical trial.","volume":"91","author":"Socias","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"jrv250039r85","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","article-title":"Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial.","volume":"73","author":"Oviedo-Joekes","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"jrv250039r86","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109869","article-title":"Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: a context-focused systematic review.","volume":"247","author":"McNair","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"jrv250039r87","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109379","article-title":"Innovating for real-world care: a systematic review of interventions to improve post-detoxification outcomes for opioid use disorder.","volume":"233","author":"Ameral","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"jrv250039r88","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/add.14964","article-title":"Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.","volume":"115","author":"Walley","year":"2020","journal-title":"Addiction"},{"issue":"5","key":"jrv250039r89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002024.pub5","article-title":"Alpha2-adrenergic agonists for the management of opioid withdrawal.","volume":"2016","author":"Gowing","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"jrv250039r90","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/ADM.0000000000000474","article-title":"Safety and efficacy of lofexidine for medically managed opioid withdrawal: a randomized controlled clinical trial.","volume":"13","author":"Fishman","year":"2019","journal-title":"J Addict Med"},{"issue":"1","key":"jrv250039r91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40122-018-0108-7","article-title":"The role of lofexidine in management of opioid withdrawal.","volume":"8","author":"Pergolizzi","year":"2019","journal-title":"Pain Ther"},{"issue":"2","key":"jrv250039r92","article-title":"Buprenorphine for managing opioid withdrawal.","volume":"2","author":"Gowing","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"jrv250039r93","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/fampra\/cmab159","article-title":"Effectiveness of non-opioid interventions to reduce opioid withdrawal symptoms in patients with chronic pain: a systematic review.","volume":"39","author":"Langejan","year":"2022","journal-title":"Fam Pract"},{"issue":"16","key":"jrv250039r94","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/ajhp\/zxae371","article-title":"Nonopioid medications for managing opioid withdrawal in acute care settings: a scoping review.","volume":"82","author":"Erstad","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"jrv250039r95","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.039","article-title":"Touchpoints\u2014opportunities to predict and prevent opioid overdose: a cohort study.","volume":"204","author":"Larochelle","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"jrv250039r96","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.2105\/AJPH.2021.306306a","article-title":"The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews.","volume":"111","author":"Razaghizad","year":"2021","journal-title":"Am J Public Health"},{"issue":"1","key":"jrv250039r97","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1186\/s12889-025-22210-8","article-title":"Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis.","volume":"25","author":"Fischer","year":"2025","journal-title":"BMC Public Health"},{"issue":"3","key":"jrv250039r98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022.","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"16","key":"jrv250039r99","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1161\/CIR.0000000000001161","article-title":"2023 American Heart Association focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care.","volume":"148","author":"Lavonas","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"jrv250039r100","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-068752","article-title":"Opioid prescribing for acute pain management in children and adolescents in outpatient settings: clinical practice guideline.","volume":"154","author":"Hadland","year":"2024","journal-title":"Pediatrics"},{"issue":"16","key":"jrv250039r101","doi-asserted-by":"publisher","first-page":"e836","DOI":"10.1161\/CIR.0000000000000958","article-title":"Opioid-associated out-of-hospital cardiac arrest: distinctive clinical features and implications for health care and public responses: a scientific statement from the American Heart Association.","volume":"143","author":"Dezfulian","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"jrv250039r102","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jama.2023.23248","article-title":"Intranasal naloxone for opioid overdose.","volume":"331","author":"Taylor","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"jrv250039r104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259126","article-title":"Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: an observational study.","volume":"16","author":"Moustaqim-Barrette","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"jrv250039r105","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15563650.2020.1758325","article-title":"Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study.","volume":"59","author":"Purssell","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"jrv250039r106","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1016\/j.jemermed.2023.05.006","article-title":"Systematic review of naloxone dosing and adverse events in the emergency department.","volume":"65","author":"Yugar","year":"2023","journal-title":"J Emerg Med"},{"issue":"5","key":"jrv250039r107","doi-asserted-by":"publisher","first-page":"110","DOI":"10.15585\/mmwr.mm7305a4","article-title":"Comparison of administration of 8-milligram and 4-milligram intranasal naloxone by law enforcement during response to suspected opioid overdose\u2014New York, March 2022-August 2023.","volume":"73","author":"Payne","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"jrv250039r108","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1080\/15563650.2023.2283391","article-title":"American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time.","volume":"61","author":"Stolbach","year":"2023","journal-title":"Clin Toxicol (Phila)"},{"key":"jrv250039r109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2024.102917","article-title":"Investigating the complexity of naloxone distribution: which policies matter for pharmacies and potential recipients.","volume":"97","author":"Smart","year":"2024","journal-title":"J Health Econ"},{"key":"jrv250039r1","volume-title":"World Drug Report 2025 (Set of 3 Booklets)","year":"2025"},{"key":"jrv250039r4","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2022","edition":"5th ed, text re"},{"key":"jrv250039r43","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"Mancher","year":"2019"},{"key":"jrv250039r7","unstructured":"Ahmad? FB, Cisewski? JA, Rossen? LM, Sutton? P. Provisional drug overdose death counts. National Center for Health Statistics. February 4, 2025. Accessed February 23, 2025. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"jrv250039r13","unstructured":"Protracted withdrawal.? Substance Abuse Treatment Advisory. 2010;9(1):1-8. Accessed February 23, 2025. https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/sma10-4554.pdf"},{"key":"jrv250039r27","unstructured":"TIP 63: Medications for Opioid Use Disorder. Substance Abuse and Mental Health Services Administration; 2021. Publication PEP21-02-01-002. Accessed August 27, 2025. https:\/\/library.samhsa.gov\/product\/tip-63-medications-opioid-use-disorder\/pep21-02-01-002"},{"key":"jrv250039r28","unstructured":"BRIXADI\u2014buprenorphine injection. DailyMed. Accessed May 29, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=5d8a8fd0-8619-422a-a664-d1d2e8970f48"},{"key":"jrv250039r29","unstructured":"SUBLOCADE\u2014buprenorphine solution. DailyMed. Accessed August 28, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6189fb21-9432-45f8-8481-0bfaf3ccde95"},{"key":"jrv250039r54","unstructured":"Statutes, regulations, and guidelines. Substance Abuse and Mental Health Services Administration. October 7, 2020. Accessed February 17, 2021. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines"},{"key":"jrv250039r58","unstructured":"Federal guidelines for opioid treatment programs. Substance Abuse and Mental Health Services Administration. Accessed December 17, 2025. https:\/\/www.med.unc.edu\/fammed\/nctac\/wp-content\/uploads\/sites\/1256\/2025\/01\/federal-guidelines-opioid-treatment-pep24-02-011-1.pdf"},{"key":"jrv250039r61","unstructured":"METHADOSE\u2014methadone hydrochloride concentrate METHADOSE SUGAR-FREE\u2014methadone hydrochloride concentrate. DailyMed. Accessed August 17, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=808a9d0b-720b-4034-a862-5122ff514608"},{"key":"jrv250039r65","unstructured":"The 42 CFR part 8 final rule table of changes. Substance Abuse and Mental Health Services Administration. Accessed May 29, 2025. https:\/\/www.samhsa.gov\/substance-use\/treatment\/opioid-treatment-program\/42-cfr-part-8\/changes"},{"key":"jrv250039r103","unstructured":"SAMHSA overdose prevention and response toolkit. Substance Abuse and Mental Health Services Administration; 2025. Publication PEP23-03-00-001. Accessed December 17, 2025. https:\/\/library.samhsa.gov\/sites\/default\/files\/overdose-prevention-response-kit-pep23-03-00-001.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2845037\/jama_harris_2026_rv_250039_1772738231.39639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:01:13Z","timestamp":1773759673000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2845037"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":109,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.26348","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}